OvaScienceSM, OVAS today provided an update on its product pipeline and
commercial plans, which are based on its egg precursor cell (EggPCSM)
technology platform. OvaScience expects to commercialize AUGMENTSM
in international in vitro fertilization (IVF) clinics in 2014 and
to launch its newest potential fertility treatment, OvaPrimeSM,
in 2015.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
